Ghana-based Center for Pharmaceutical Advancement and Training
(Cepat), a piece of the U.s. Pharmacopeial Convention's (USP) Global Health
Impact Program, is presently utilizing anti-counterfeiting technology in its
battle to recognize fake anti-malaria drugs, a real issue in Ghana and
Sub-Saharan Africa.
Thermo Scientific Truscan instruments are perfect for the Cepat
exertion due to their streamlined client interface, simplicity of execution and
inalienable specificity, intended to permit key work force at the purpose of
need to rapidly and faultlessly recognize fake medications.
Get
detailed report at: http://www.reportsandintelligence.com/anti-counterfeit-market
“Malaria is a major health issue in this region and anti-malarial
drugs are critical to survival,” said Dr. Patrick Lukulay, vice president at
USP in charge of the Promoting Quality of Medicines program.
“Sadly, counterfeiters are exploiting this need and attempting to
capitalize, and we need ways to stay ahead of them. Because TruScan is easy to
learn and delivers immediate results, we’re able to make it an integral part of
our ongoing effort to safeguard the public and improve human health.”
We’re pleased to play a role in a very important
public health issue,” said Bob Brush, business development manager at Thermo
Fisher Scientific. “The work CePAT is doing is precisely what we designed
TruScan to do, make it easy to confirm that a substance – whether it’s a pill,
powder or liquid and even if it’s already packaged and shipped – is what it
says it is.”
Anti-Counterfeiting is increasingly becoming
important as a result of increased product duplication. As per Reports and
Intelligence, the Anti-Counterfeiting market would reach a market value of
142.7 billion by 2020.
No comments:
Post a Comment